About GRIN Therapeutics

GRIN Therapeutics was founded when Dr. Pierandrea Muglia met the GRIN community at the 2019 CFERV Conference on GRIN Variants at Emory University, in Atlanta. Dr. Muglia came arrived knowing that radiprodil had a mechanism suggesting it might help patients with gain of function genetic variants in GRIN2B. What he didn’t expect was the maturity of the work produced by the GRIN community—from clinicians, researchers, advocates, and families working together. This inspired him to form GRIN Therapeutics to develop potential a treatment for the GRIN community. This passion has fed and inspired our small, patient-focused team. Early success in GRIN-NDD has spurred exploration into other neurodevelopmental disorders involving NMDA receptor dysregulation.